AI Article Synopsis

  • Cancer is caused by genetic changes in cells, and recent studies have pinpointed several common mutations associated with various cancers, but their relevance to ovarian carcinomas is unclear.
  • A study of 251 ovarian carcinoma patients found no evidence of mutations in key genes previously linked to cancer, suggesting they may not contribute to ovarian cancer development.
  • The study did discover mutations in other genes related to specific ovarian cancer subtypes, indicating that different genetic factors may drive the carcinogenesis of endometrioid and mucinous ovarian carcinomas.

Article Abstract

Cancer is caused by multiple genetic alterations within cells. Recently, large-scale sequencing has identified frequent ribonuclease type III (), CCCTC-binding factor (), ribosomal protein L22 (), DNA (cytosine-5-)-methyltransferase 3α (), transformation/transcription domain-associated protein (), isocitrate dehydrogenase ()1 and hotspot mutations in diverse types of cancer. However, it remains largely unknown whether these mutations also exist in ovarian carcinomas. In the present study, a collection of 251 patients with distinct subtypes of ovarian carcinomas were recruited and sequenced for the presence of these hotspot mutations. However, no mutations in the seven genes were detected in the samples. These negative results, together with certain recent reports, indicate that the hotspot mutations in the and genes may not be actively involved in the carcinogenesis of ovarian carcinoma. Of note, the mutation frequency in Sertoli-Leydig cell tumor in the present study was significantly lower compared to prior observation, and therefore, it is speculated that this discrepancy may be mainly due to the small sample size analyzed in the study. In addition, among these samples, frequent polymerase (DNA directed) ε, catalytic subunit () and ring finger protein 43 () mutations were identified in endometrioid and mucinous ovarian carcinomas, respectively; thus and hotspot mutations may not play synergistic roles with or mutations in the carcinogenesis of endometrioid or mucinous ovarian carcinomas.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251111PMC
http://dx.doi.org/10.3892/br.2014.378DOI Listing

Publication Analysis

Top Keywords

hotspot mutations
20
ovarian carcinomas
20
mutations
9
subtypes ovarian
8
mutations genes
8
endometrioid mucinous
8
mucinous ovarian
8
ovarian
6
carcinomas
5
absence hotspot
4

Similar Publications

Background: Multi-cancer early detection (MCED) through a single blood test significantly advances cancer diagnosis. However, most MCED tests rely on a single type of biomarkers, leading to limited sensitivity, particularly for early-stage cancers. We previously developed SPOT-MAS, a multimodal ctDNA-based assay analyzing methylation and fragmentomic profiles to detect five common cancers.

View Article and Find Full Text PDF

Unlabelled: QUESTIONS AND RECOMMENDATIONS FROM THE PRIOR VERSION OF THESE GUIDELINES WITHOUT CHANGE: TARGET POPULATION: Adult patients (age ≥ 18 years) who have suspected low-grade diffuse glioma.

Question: What are the optimal neuropathological techniques to diagnose low-grade diffuse glioma in the adult?

Recommendation: Level I Histopathological analysis of a representative surgical sample of the lesion should be used to provide the diagnosis of low-grade diffuse glioma. Level III Both frozen section and cytopathologic/smear evaluation should be used to aid the intra-operative assessment of low-grade diffuse glioma diagnosis.

View Article and Find Full Text PDF

The GPCR autoproteolysis inducing (GAIN) domain is an ancient protein fold ubiquitous in adhesion G protein-coupled receptors (aGPCR). It contains a tethered agonist necessary and sufficient for receptor activation. The GAIN domain is a hotspot for pathological mutations.

View Article and Find Full Text PDF

The emergence of SARS-CoV-2 variants of concern (VOCs) has greatly diminished the neutralizing activity of previously FDA-approved monoclonal antibodies (mAbs), including that of antibody cocktails and of first-generation broadly neutralizing antibodies such as S309 (Sotrovimab). In contrast, antibodies targeting cryptic conformational epitopes of the receptor binding domain (RBD) have demonstrated broad activity against emerging variants, but exert only moderate neutralizing activity, which has so far hindered clinical development. Here, we utilize in vitro display technology to identify and affinity-mature antibodies targeting the cryptic class 6 epitope, accessible only in the "up" conformation of the SARS-CoV-2 spike trimer.

View Article and Find Full Text PDF

Purpose: 10-15% of prostate cancers (PCa) harbor recurrent FOXA1 aberrations whereby the alteration type and the effect on the forkhead( FKH) domain impacts protein-function. We developed a FOXA1 classification system to inform clinical management.

Experimental Design: 5,014 PCa were examined using whole exome and transcriptome sequencing from the Caris database.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!